Hsbc Holdings PLC Acquires 1,230,957 Shares of Kenvue Inc. $KVUE

Hsbc Holdings PLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 31.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,106,368 shares of the company’s stock after buying an additional 1,230,957 shares during the quarter. Hsbc Holdings PLC’s holdings in Kenvue were worth $88,231,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KVUE. Physician Wealth Advisors Inc. lifted its stake in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the last quarter. Elyxium Wealth LLC bought a new stake in Kenvue during the 4th quarter worth $26,000. MV Capital Management Inc. bought a new stake in Kenvue during the 4th quarter worth $28,000. Reflection Asset Management acquired a new position in Kenvue in the 4th quarter worth about $32,000. Finally, SBI Securities Co. Ltd. increased its holdings in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.59% of the stock is currently owned by insiders.

Kenvue Stock Performance

NYSE:KVUE opened at $19.81 on Friday. The company has a market capitalization of $38.03 billion, a PE ratio of 23.30, a P/E/G ratio of 1.50 and a beta of 0.47. The company has a 50 day simple moving average of $17.86 and a two-hundred day simple moving average of $17.71. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $22.87.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the previous year, the company earned $0.24 EPS. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. Research analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KVUE. Citigroup dropped their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Barclays dropped their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. UBS Group decreased their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Finally, Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.